Previous 10 | Next 10 |
Gainers: China Bat Group (NASDAQ: GLG ) +66% . Papa Murphy's Holdings (NASDAQ: FRSH ) +31% . Phunware (NASDAQ: PHUN ) +22% . Evofem Biosciences (NASDAQ: EVFM ) +18% . American Renal Associates Holdings (NYSE: ARA ) +15% . Acer Therapeutics (NASDAQ: ACER ) +14% . ZK Internation...
The following slide deck was published by Acer Therapeutics Inc. in conjunction with this Read more ...
The following slide deck was published by Acer Therapeutics Inc. in conjunction with this Read more ...
In a release issued earlier today by Acer Therapeutics Inc. (Nasdaq: ACER), please note in the table for the Roth Capital Partners 31 st Annual Growth Stock Conference, a time of 3:30 pm Pacific Time has been added for the Fireside Chat. The corrected release follows: NEWTON, ...
NEWTON, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that ...
Acer Therapeutics (NASDAQ: ACER ): Q4 GAAP EPS of -$0.85. More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEWTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today reported financ...
Data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. On September 25, 2018 I published my first article on Acer in which I described the Company's history and its business plan to focus on ...
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that i...
Acer Therapeutics (NASDAQ: ACER ) announces that the FDA has accepted for review Acer’s NDA for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. More news on: Acer Therapeutics Inc., Healthcare sto...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023